Clover Health Investments

CLOV

Market cap $1.15B

CLOV rides strong membership growth and an AI-driven care model, but rising costs and policy risks cloud the near-term outlook.

WILMINGTON, Del., April 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Wednesday, May 6, 2026.

WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, in partnership with  HealthEx , today announced a new collaboration that enables Clover Medicare Advantage (MA) members to securely access and share clinical records and claims data, further advancing patients rights to access and share their own health data, which is central to federal interoperability efforts.

WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Peter Kuipers is stepping down as the Chief Financial Officer of the Company, effective March 30, 2026. Mr. Kuipers will remain with the Company in an advisory capacity through April 24, 2026 to support a smooth transition and handoff. Mr. Kuipers and the Company noted that his departure does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

SAN FRANCISCO, March 19, 2026 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), and a leading AI-powered physician-enablement platform today released a whitepaper titled  “Driving Clinical Excellence in Chronic Disease: Counterpart Assistant's Role in Flu Preventative Care.” The analysis examines the role of CA's real-time clinical insights on immunization rates and flu-related acute care utilization within Clover Health's Medicare Advantage (MA) population.

Clover Health is positioned for a major turnaround, with operations and profitability metrics improving sharply despite market skepticism. CLOV projects 46% membership growth and 49% revenue growth for 2026, guiding toward its first full year of positive GAAP net income. Operating leverage is materializing as SG&A improves, member retention exceeds 95%, and mature cohorts deliver over $200 monthly profit per member.

NOTICE: This is an updated version of a press release originally issued March 4, 2026 by Clover Health Investments, Corp. (Nasdaq: CLOV). Language has been updated to further refine the description of Clover Health's participation in federal interoperability initiatives.

CLOV jumped 8% after partnering with Kno2 to become the first payer live on a CMS Aligned Network, enabling real-time patient access to clinical and claims data.

CLOV rides 38% Medicare Advantage growth and rising EBITDA, but higher medical costs and policy risks cloud its near-term margin outlook.

WILMINGTON, Del., March 04, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, and Kno2, healthcare's leading communication network, today announced a collaboration enabling Clover Health to be the first payer live on a CMS Aligned Network and TEFCA.